id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-330089-926y1hfj	Russo, Vincenzo	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients	2020-10-08		.txt	text/plain	2646	153	42	INTRODUCTION: No data are provided about the effect of triple combination therapy with Lopinavir/Ritonavir (LPN/RTN), hydroxychloroquine (HQ) and azithromycin (AZT) on corrected QT (QTc) interval and arrhythmic risk, in COVID-19 patients. No data are provided about the effect of triple combination therapy with Lopinavir/Ritonavir (LPN/RTN), hydroxychloroquine (HQ) and azithromycin (AZT) on corrected QT (QTc) interval and arrhythmic risk, in COVID-19 patients. The concomitant use of three or more QT prolonging drugs twice increases the risk of QT prolongation in hospitalized patients on cardiology ward (Khan et al., 2017) ; however, no data on the effect of triple combination therapy with LPN/RTN, HQ and AZT on corrected QT (QTc) interval and arrhythmic risk have been still provided. We observed a high incidence of extreme QTc interval prolongation among COVID-19 patients on triple combination therapy with lopinavir-ritonavir, azithromycin and hydroxychloroquine, leading to discontinuation of pharmacological treatments in about half the cases.	./cache/cord-330089-926y1hfj.txt	./txt/cord-330089-926y1hfj.txt